Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Awareness, Care & Treatment in Obesity Management (ACTION) Study

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Other: No treatment given

First Posted Date: 2017-07-21

Last Posted Date: 2019-07-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 3767

Registration Number: NCT03223493

Locations: 🇺🇸
Novo Nordisk Investigational Site, Honeoye Falls, New York, United States

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: NPH insulin
Drug: Insulin detemir

First Posted Date: 2017-07-18

Last Posted Date: 2017-07-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 752

Registration Number: NCT03220425

Locations: 🇬🇧
Novo Nordisk Investigational Site, York, United Kingdom

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: Faster-acting insulin aspart
Drug: Insulin aspart

First Posted Date: 2017-07-12

Last Posted Date: 2019-03-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 58

Registration Number: NCT03215498

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

Phase 1

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency
Growth Hormone Deficiency in Children

Interventions: Drug: Somapacitan

First Posted Date: 2017-07-11

Last Posted Date: 2019-05-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 34

Registration Number: NCT03212131

Locations: 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Phase 2

Completed

Conditions: Haemostasis
Haemophilia A

Interventions: Drug: Concizumab
Drug: Turoctocog alfa

First Posted Date: 2017-06-22

Last Posted Date: 2021-11-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT03196297

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Phase 2

Completed

Conditions: Haemophilia B With Inhibitors
Congenital Bleeding Disorder
Haemophilia A With Inhibitors

Interventions: Drug: Concizumab
Drug: Eptacog alfa

First Posted Date: 2017-06-22

Last Posted Date: 2021-10-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT03196284

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Liraglutide
Drug: Semaglutide

First Posted Date: 2017-06-19

Last Posted Date: 2019-10-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 577

Registration Number: NCT03191396

Locations: 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

Phase 1

Completed

Conditions: Adult Growth Hormone Deficiency
Growth Hormone Disorder
Growth Hormone Deficiency in Children

Interventions: Drug: Somapacitan

First Posted Date: 2017-06-14

Last Posted Date: 2020-04-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 44

Registration Number: NCT03186495

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2017-06-07

Last Posted Date: 2021-11-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 10

Registration Number: NCT03179748

Locations: 🇲🇽
Novo Nordisk Investigational Site, Monterrey, Nuevo León, Mexico

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide
Drug: Insulin degludec

First Posted Date: 2017-06-05

Last Posted Date: 2020-03-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 453

Registration Number: NCT03175120

Locations: 🇭🇰
Novo Nordisk Investigational Site, Shatin, New Territories, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy